

NAFLD

By 1 1

Reduction of Plasma Adiponectin in Egyptian obese children with Nonalcoholic Fatty Liver Disease

ABSTRACT:

Purpose: Obesity, insulin resistance and dyslipidemia are the most significant risk factors of non-alcoholic fatty liver disease (NAFLD) in children, and consider a major cause of liver-related morbidity. The aim of the study was to evaluate the serum levels of adiponectin, leptin and fasting insulin in obese children with NAFLD to explore the role of adiponectin in the pathogenesis of this disease.

Material and Methods: The fasting serum levels of adiponectin, leptin, glucose, insulin, ALT, AST, total bilirubin, direct bilirubin, albumin, alkaline phosphatase, creatinine, cholesterol, triglycerides, HDL, LDL, GGT and CRP in a group of 50 NAFLD children were measured after doing ultrasonography and 40 participants as controls with comparable age, sex and body-mass index.

Results: Plasma adiponectin was significantly lower in NAFLD children than controls (3.23 ± 2.5 vs 11.0 ± 2.95 ng/dl). Moreover, NAFLD group had significantly higher insulin resistant, fasting insulin 11.4 ± 4.9 vs 4.7 ± 3.1 μ u/l in comparison with control group, while regarding to serum leptin there is no significant difference. An inverse correlation was observed between adiponectin and homeostatic model assessment (HOMA-IR), fasting insulin, leptin, triglycerides, ALT, AST, GGT and BMI.

Conclusion: These data support a role for low circulating adiponectin in the pathogenesis of NAFLD and its association with insulin resistance.

Key words: Non-alcoholic fatty liver, adiponectin, leptin and Obesity

INTRODUCTION:

5

At present, non alcoholic fatty liver disease (NAFLD) is identified as an important liver disease in children, occurring even in the very young (1). The incidence in the general population is 2.6% but increases to 53% in obese children; thus, NAFLD is expected to become the most common cause of pediatric chronic liver disease (2). NAFLD prevalence is increasing, alongside obesity, essentially because of sedentary lifestyles and high caloric diets (3). NAFLD is considered the hepatic manifestation of the metabolic syndrome, which is characterized by insulin resistance, visceral obesity, hypertension, dyslipidemia, and abnormalities of fasting serum glucose levels. Pediatric patients with NAFLD have been shown to exhibit higher levels of insulin, total

cholesterol, triglycerides, low-density lipoprotein cholesterol, and fasting glucose, as well as higher blood pressure values than obese children without NAFLD. Moreover, children with metabolic syndrome are more likely to display NAFLD than those children without metabolic syndrome (4). NAFLD is characterized by fat accumulation in the liver (steatosis) and insulin resistance, influenced by genetic susceptibility, epigenetic mechanisms, a sedentary lifestyle, and high caloric diets (5). Hepatic triglyceride accumulation results from increased delivery of free fatty acid to the liver, increased lipogenesis, and impaired fatty acid metabolism in hepatocytes. Hepatic fat accumulation has been shown to exacerbate insulin resistance by interfering with phosphorylation of insulin receptor substrates (6). Adipocytes or inflammatory cells infiltrating the adipose tissue in insulin resistance are responsible for adipocytokine secretion (7). The adiponectin is highly abundant in human serum and is secreted by adipose tissue in inverse proportion to the body mass index (8). Adipocytokines, including adiponectin, leptin, resistin and tumour necrosis factor-alpha, also appear to be involved in the progression of simple steatosis to non alcoholic steatohepatitis (9).

NAFLD refers to a wide spectrum of liver abnormalities ranging from simple liver steatosis (fat accumulation in the liver) to steatohepatitis (non-alcoholic steatohepatitis NASH), which may be associated with fibrosis and progress to cirrhosis and end-stage liver disease (9). Cirrhosis in children is rare but is reported. NAFLD has no specific symptoms or signs but should be considered in obese children. NAFLD does not have a proven treatment. Weight loss with family based treatments is the most acceptable management. Exercise and an applicable diet with low glycemic index and appropriate calorie intake are preferred. Drugs are promising but not sufficient in children for today (10). So, we aimed in this study to assess the relationship between selected adipokines in non alcoholic fatty liver disease to explore its role in the pathogenesis of this disease in obese children.

PATIENTS AND METHODS:

The study was carried out prospectively with 50 obese children (mean BMI 34.6 ± 5.5 , mean age 13 ± 2.69 , range 5-16, 30 boys and 20 girls, with a suspected liver disease (hepatomegaly and/or ultrasonographic liver brightness and/or increased ALT level), who were admitted to out-patients, clinic El Sahel Teaching Hospital between August 2012 and October 2013; in comparison with 40 control subjects (15 male, 25 female) with (mean BMI 25.8 ± 4.6 , mean age 9.05 ± 3.2 , range 6-15).

The diagnosis of NAFLD was based on the standard criteria accepted by the American Gastroenterology Association (AGA) by ultrasonographic finding of bright liver (11) that is defined as abnormally intense, high level echoes arising from the hepatic

parenchyma, with amplitude similar to that of echoes arising from the diaphragm and elevation of serum ALT activity.

An informed consent was obtained from all patients' parents. The study was carried out in accordance with the principles of the Declaration of Helsinki, and its appendices, and local and national laws.

The viral hepatitis (hepatitis B virus-HBV, hepatitis C virus-HCV, cytomegalo virus-CMV), toxic, autoimmune (AIH) and metabolic liver diseases (Wilson disease, α -1 antitrypsin deficiency, cystic fibrosis) were excluded by ELISA technique for both HBs (HBV) Ag and HCV Ab using (Axiom GmbH Germany) and for CMV IgG using (Organon Laboratories Helsinki FINLAND) for both cases and controls.

The body mass index (BMI) was calculated as the weight (kilograms) divided by the height (meters) squared in all children.

Blood sampling and biochemical assays

A blood sample was collected after overnight fasting for both patient and control groups. portion of blood was allowed to clot and then centrifuged at 3500g for 5 min to separate the serum used for assessment of serum level of total cholesterol, triglycerides, lipoproteins: high density (HDL) and low density (LDL) as well as standard liver tests including (total bilirubin, direct bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), albumin) using Beckman CX4 chemistry analyzer (BMY, USA, supplied by the Eastern Co. For Eng. & Trade-Giza,Egypt). Serum aliquots were stored at -80 C until assayed and thawed immediately before the measurements of adiponectin, leptin, and CRP levels. A diponectin, leptin, fasting insulin and C-reactive protein (CRP) were measured by ELISA technique.

EASIA is a solidphase enzyme-amplified sensitivity immunoassay performed on microtiter plate with a sensitivity of 0.1 ng/ ml and intra-assay 3.6%.

The insulin resistance was assessed from fasting insulin and fasting glucose by homeostasis model (HOMA-IR) (12).

HOMA-IR was calculated using the following formula (12):

$$\text{HOMA-IR} = \frac{\text{fasting serum glucose (mg/dl)} \times \text{fasting insulin } (\mu\text{U/ml})}{405}.$$

Laboratory evaluations:

Serum level of adiponectin was determined with a commercially available AssayMax Human Adiponectin ELISA kit (Cat. No: EA2500-1, Assaypro, St. Charles, MO, USA) with sensitivity 0.5 ng/ml, and intra-assay and inter-assay variations were 4.1% and

7.2%, respectively. This assay employs a quantitative sandwich enzyme immunoassay technique. Serum level of leptin was measured using the BioSource[®] leptin EASIA kit (Cat. No: KAP2281; BioSource Europe S.A, Nivelles, Belgium). The levels of serum hs-CRP were determined by Accu-Bind ELISA Kit (Monoclonal Inc, USA).) and serum insulin (determined by ELISA using commercial Human kit). All assays were performed in duplicate according to the manufacturer's instructions.

STATISTICAL ANALYSIS:

Results are expressed as mean $\pm$ standard deviation (SD). Case and control groups were compared by student's t-test for independent values with Bonferroni correction. Correlations between different variables were determined by logarithmic regression and multivariate analysis. P values less than 0.05 were considered significant.

RESULTS:

Anthropometric, clinical and biochemical parameters are illustrated in Tables 1 and 2. No significant difference were observed in HDL, bilirubin (T, D), albumin, creatinine, ALP, T. cholesterol, triglyceride and Leptin, while fasting glucose, plasma insulin, HOMA, ALT, LI, GGT and CRP were significantly higher in NAFLD patients than control subjects. Plasma adiponectin was significantly lower in NAFLD group than controls. When correlation analysis was performed, adiponectin levels were inversely correlated with triglycerides ($r=-0.348$, $P<0.0001$), with insulin ($r=-0.509$, $P<0.0001$), with HOMA (-0.445 , $P<0.0001$), with leptin ($r=0.725$, $P<0.0001$), with ALT ($r=-0.534$, $P<0.0001$), with AST ($r=-0.554$, $P<0.0001$), with GGT ($r=-0.461$, $P<0.0001$) and with BMI ($r=-0.593$, $P<0.0001$). At the same time leptin showed a positive correlations with ALT and BMI ($r=0.548$, $P<0.0001$ & $r=0.612$, $P<0.0001$) respectively. In NAFLD group, serum aminotransferases are moderately high with ALT being higher than AST and ALT/AST ratio = 1.14.

Table 1 Anthropometric and clinical characteristics of NAFLD patients and control subjects

parameters	NAFLD Mean $\pm$ SD	Control Mean $\pm$ SD	P Value
M/F	30/20	15/25	NS

Age (year)	13.0±2.6	9.05±3.2	NS
BMI (Kg/m ²)	34.6±5.5	25.8±4.6	<0.0001

20

Table 2: Biochemical parameters of NAFLD and control subjects

parameters	NAFLD (N:50) Mean± SD	Control (N:40) Mean± SD	P Value
Fasting glucose(mg/dl)	143±32.9	101±15.4	<0.0001
fasting insulin(mU/l)	11.4±4.9	4.7± 3.1	<0.0001
T.cholesterol(mg/dl)	170 ±29	164 ±29	NS
HDL cholesterol(mg/dl)	40±9.6	43 ± 8.0	NS
LDL cholesterol(mg/dl)	130±27.5	108±11.2	<0.0001
Triglycerides (mg/dl)	192±37	156±31	<0.0001
HOMA	4.13±2.29	1.21±0.97	<0.0001
T. Bilirubin (mg/dl)	1.35±0.7	0.73±0.2	<0.0001
D. Biliurbin (mg/dl)	0.31±0.19	0.14±0.05	<0.0001
AST (U/l)	58.5±22.4	29.6±8.9	<0.0001
ALT (U/l)	63.3±30.4	27.8±6.1	<0.0001
GGT(U/l)	34.9±9.7	54.1±21.0	<0.0001
Alb g/dl	3.6±0.5	3.9±0.2	<0.0001
Leptin(ng/dl)	13.1±3.2	4.8±2.3	<0.0001
Adiponectin(ng/dl)	3.23±2.5	11.0±2.95	<0.0001
CRP	18.7±13.2	4.99±3.2	<0.0001
Creatinine (mg/dl)	0.79±0.35	0.98±0.19	<0.0001
Alkaline (U/l)	215±56.5	188±42.5	<0.05




Figure (1) Serum levels of Adiponectin in different studied groups.




Figure (2) Serum levels of fasting insulin in different studied groups




Figure (3) Serum levels of ALT and Adiponectin in different groups




Figure (4) Correlation between serum levels of Adiponectin and Triglycerides




Figure (5) Correlation between serum levels of Adiponectin and Insulin




Figure (6) Correlation between serum levels of Adiponectin and HOMA




Figure (7) Correlation between serum levels of Adiponectin and BMI




Figure (8) Correlation between serum levels of Adiponectin and Leptin




Figure (9) Correlation between serum levels of Leptin and BMI




Figure (10) Correlation between serum levels

DISCUSSION:

Fatty liver is a growing health problem worldwide. The important risk factors for NAFLD in children are obesity and insulin resistance. In general, NAFLD has no specific symptoms or signs but should be considered in obese children. The most common admission reason is slightly elevated transaminases or coincidentally noticed hepatomegaly. ALT being higher than AST.

In our study, NAFLD prevalence appears to increase with age, with a mean age at 13 years and with a male-to-female ratio 3:2 and these results are in agreement with data presented by (13,14) and who suggested that NAFLD prevalence increases with age, with a mean age at diagnosis between 11 and 13 years. This tendency is likely explained by adolescent hormonal changes, which result in an increase in serum insulin levels and fat accumulation in the liver (15,16,17). Alisi and his associates (3) found that, according to epidemiological data, NAFLD in children increase in male than female in ratio 2:1.

We confirmed lower adiponectin level in children with NAFLD than in controls and these results are in agreement with data presented by Claudio et al. (18), Louthan et al. (19), Zou et al. (20), Burgert et al. (21) and Lebensztejn et al. (22). We also found no differences in the leptin levels between the group of children with NAFLD and controls and these results are consistent with the study of Mandato et al. (23). Many authors found correlation between BMI and serum leptin (22,24,25,26) which is consistent with our findings. Hypoadiponectinemia was shown to be responsible for the accumulation of hepatic fat as well as the development of insulin resistance (27). This finding is consistent with our study because we also confirmed a negative correlation between adiponectin and insulin resistance (HOMA-IR). Insulin resistance is common in obese

children and it plays a major role in the pathogenesis of NAFLD (28). It may play a role not only in the development of steatosis but also in the development of liver fibrosis by increasing hepatic fatty acid beta-oxidation stress (29). We also found a negative correlation between ALT, AST & GGT and adiponectin in children with NAFLD and these results are in agreement with Lopez-Bermejo et al. (30) who reported that adiponectin levels were significantly correlated with ALT, GGT and ALP; thus suggesting a wider role for adiponectin in the maintenance of liver integrity. Also Lebensztejn et al. (22) and Miriam et al. (31) found a negative correlation of serum adiponectin and ALT activity, which is consistent with our finding. Lebensztejn et al. (22) reported that studies performed in children have special value because children could be regarded as an ideal model for the study of natural history and pathogenesis of obesity related liver disease for the earlier stages of the disease, absence of major confounding factor of liver pathology such as alcohol consumption and other environmental influences, often seen in adults.

CONCLUSION:

Our study reported a lower plasma adiponectin in NAFLD children that is inversely correlated with insulin resistance (HOMA-IR), ALT, AST and GGT. These data support a role for adiponectin in protection against liver injury and put adiponectin to be suitable serum marker in predicting liver steatosis in children with NAFLD but these finding needs to be confirmed in larger studies. We recommend a large-scale screening in the high-risk population, especially among the overweight pediatric patients, should be considered, including measurement of serum transaminases, plasma adiponectin and liver ultrasound, it is crucial to treat this condition as soon as possible in order to avoid the progression to end stage liver disease.

FUNDING:

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

CONFLICT OF INTEREST:

All The authors declare that they have no competing interests.

REFERENCES:

- 1- Barshop NJ, Sirlin CB, Schwimmer JB and Lavine JE (2008): Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. *Aliment Pharmacol Ther*; 28: 13-24.

- 2- Patton HM, Sirlin C, Behling C, Middleton M, et al. (2006): Pediatric non alcoholic fatty liver disease: a critical appraisal of current data and implications for future research. *J PediatrGastroenterolNutr*; 43: 413-27.
- 3- Alisi A, Manco M, Vania A and Nobili V. (2009): Pediatric non alcoholic fatty liver disease in 2009. *J Pediatr* 155: 469-474.
- 4- Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK and Cook S (2008): Cardiovascular risk factors and the metabolic syndrome in pediatric non alcoholic fatty liver disease. *Circulation* 118: 227-283.
- 5- Nobili V, Svegliati-Baroni G, Alisi A et al. (2012): A 360-degree overview of pediatric NAFLD: recent insights. *J Hepatol* 58(6): 1218-1229.
- 6- Samuel VT, Liu ZX, Qu X, Elder BD, et al. (2004): Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. *J BiolChem* 279: 32345-32353.
- 7- Yesim O and Ozlem BS (2014): Fatty liver in childhood. *World Journal ofHepatology*; 6(1): 33-40.
- 8- Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, et al. (1999): Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *BiochemBiophys Res Commun*; 257: 79-83.
- 9- Berardis S. and Sokal E. (2014): Pediatric non-alcoholic fatty liver disease: an increasing public health issue. *Eur J Pediatr*; 137: 131-139.
- 10- Ozturk Y and Soylu OB (2014): Fatty liver in childhood *World J Hepatol*; 6(1): 33-40.
- 11- Sanyal AJ AGA technical review on nonalcoholic fatty liver disease. *Gastroenterology*. 2002;123:1705-1725.
- 12- Mathews DR, Hosker JP, Rudenski AS, et al. (1985): Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia*. Jul; 28(7): 412-9.
- 13- Schwimmer JB, Celedon MA, Lavine JE, Salem R, et al. (2009): Heritability of nonalcoholic fatty liver disease. *Gastroenterology*; 136: 1585-1592.
- 14- Widhalm K, Ghods E (2010): Nonalcoholic fatty liver disease: a challenge for pediatricians. *Int J Obes (Lond)* 34: 1451-1467.
- 15- Roberts EA (2007): Pediatric non alcoholic fatty liver disease (NAFLD): a “growing” problem? *J Hepatol* 46: 1133-1142.
- 16- Romeo S, Huang-Doran I, Baroni MG and Kotronen A. (2010): Unravelling the pathogenesis of fatty liver disease: palatin like phospholipase domain-containing 3 protein. *CurrOpinLipidol*; 21: 247-252.
- 17- Deboer MD (2011): Ethnicity, obesity and the metabolic syndrome: implications on assessing risk and targeting intervention. *Expert Rev EndocrinolMetab*; 6: 279-289.

- 18- Claudio P, Giorgio S, Walter E, et al. (2005): Plasma adiponectin is decreased in non alcoholic fatty liver disease. *European Journal of Endocrinology*; 152: 113-118.
- 19- Louthan MV, Barve S, McClain CJ and Joshi-Brave S (2005): Decreased serum adiponectin: an early event in pediatric non alcoholic fatty liver disease. *J Pediatr. Dec*; 147(6): 835-8.
- 20- Zou CC, Liang L., Hong F, Fu JF and Zhao ZY (2005): Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children. *Endocr J. Oct*; 52(5): 519-24.
- 21- Burgert TS, Taksali SE, Dziura J, Goodman TR, et al. (2006): Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin and visceral fat. *J ClinEndocrinolMetab. Nov*; 91(11): 4287-94.
- 22- Lebensztein DM, Wojtkowska M, Skiba E, Werpachowska L, Tobolczyk J and Kaczmarek M (2009): Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease. *Advances in Medical Sciences. Vol 54(2)*: 177-182.
- 23- Mandato C, Lucariello S, Licenziati MR, et al. (2005): Metabolic, hormonal, oxidative and inflammatory factors in pediatric obesity – related liver disease. *J Pediatr. Jul*; 147(1): 62-6.
- 24- Uygun A, Kadayifci A, Yesilova Z, Erdil A., et al. (2000): Serum leptin levels in patients with non alcoholicsteatohepatitis. *Am J Gastroenterol. Dec*; 95(12): 3584-9.
- 25- Nakamuta M, Tada S, Uchimura K, Enjoji M., et al. (2001): Serum leptin levels in patients with nonalcoholic chronic liver disease. *Hepatogastroenterology. Mar-Apr*; 48(38): 527-32.
- 26- Steinberger J, Steffen L., Jacobs DR, Moran A, Hong CP and Sinaiko AR (2003): Relation of leptin to insulin resistance syndrome in children. *Obes Res.*, Sep; 11(9): 1124-30.
- 27- Musso G, Gambino R, Durazzo M, Biroli G, Carello M., et al. (2005): Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. *Hepatology. Nov*; 42(5): 1175-83.
- 28- Ciba I and Widhalm K (2007): The association between non-alcoholic fatty liver disease and insulin resistance in 20 obese children and adolescents. *ActaPaediatr. Jan*; 96(1): 109-12.
- 29- Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. (2001): Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. *Gastroenterology, Apr*; 120(5): 1183-92.

UNDER PEER REVIEW

- 30- Lopez-Bermejo A, Botes P, Funahashi T, Delgado E, Kihara S, Ricart W and Manual FJ (2004): Adiponectin, hepatocellular dysfunction and insulin sensitivity. *Clinical Endocrinology*; 60, 256-263.
- 31- Miriam VL, Shirish B, Craig J and Swati JB (2005): Decreased Serum Adiponectin: An Early Event in Pediatric Non-alcoholic Fatty Liver Disease, *The Journal of Pediatrics*; 147, 835-838.

NAFLD

ORIGINALITY REPORT

38%

SIMILARITY INDEX

PRIMARY SOURCES

- 1

D M Lebensztejn. "Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease", *Advances in Medical Sciences*, 12/01/2009
CrossCheck

327 words — 9%
- 2

Berardis, S., and E. Sokal. "Pediatric non-alcoholic fatty liver disease: an increasing public health issue", *European Journal of Pediatrics*, 2014.
CrossCheck

325 words — 9%
- 3

Sadik, N. A. H., A. Ahmed, and S. Ahmed. "The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients", *Human & Experimental Toxicology*, 2012.
CrossCheck

143 words — 4%
- 4

www.eje.org
Internet

138 words — 4%
- 5

www.medworm.com
Internet

45 words — 1%
- 6

Bruno, Graziella Fornengo, Paolo Novelli. "C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study.(ORIGINAL ART", *Diabetes*, April 2009 Issue
Publications

40 words — 1%
- 7

C. Pagano. "Plasma adiponectin is decreased in nonalcoholic fatty liver disease", *European Journal of Endocrinology*, 01/01/2005
CrossCheck

33 words — 1%
- 8

nej.sagepub.com
Internet

30 words — 1%

9	www.thefreedictionary.com Internet	22 words – 1%
10	atvb.ahajournals.org Internet	22 words – 1%
11	www.asmr.eg.net Internet	22 words – 1%
12	www.wjgnet.com Internet	22 words – 1%
13	V. W. S. WONG. "Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease", <i>Alimentary Pharmacology and Therapeutics</i> , 10/2006 CrossCheck	19 words – 1%
14	"Development and validation of a simple index system to predict nonalcoholic fatty liver disease", <i>Korean Journal of Hepatology</i> , 2011. Publications	18 words – < 1%
15	Bozzetto, Lutgarda Prinster, Anna Annuzz. "Liver fat is reduced by an isoenergetic MUFA diet in a controlled randomized study in type 2 diabeti", <i>Diabetes Care</i> , July 2012 Issue Publications	16 words – < 1%
16	www.ncbi.nlm.nih.gov Internet	16 words – < 1%
17	www.if-pan.krakow.pl Internet	14 words – < 1%
18	Birgitte Lindegaard. "High Plasma Level of Interleukin-18 in HIV-Infected Subjects With Lipodystrophy", <i>JAIDS Journal of Acquired Immune Deficiency Syndromes</i> , 05/2004 CrossCheck	14 words – < 1%
19	jcrpe.org Internet	13 words – < 1%
20	Nicola Villanova. "Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease", <i>Hepatology</i> , 08/2005	11 words – < 1%

- | | | |
|----|---|----------------|
| 21 | www.fegato.it
<small>Internet</small> | 9 words – < 1% |
| 22 | www.fedoa.unina.it
<small>Internet</small> | 9 words – < 1% |
| 23 | Henze, Andrea Espe, Katharina M. Wanner,.
"Transthyretin predicts cardiovascular outcome in
hemodialysis patients with type 2 diabetes.(ORIGINA", Diabetes
Care, Nov 2012 Issue
<small>Publications</small> | 9 words – < 1% |
| 24 | www.jofamericanscience.org
<small>Internet</small> | 8 words – < 1% |
| 25 | "OBESITY--PATHOGENISIS.", Diabetes/00121797,
20080602
<small>Publications</small> | 8 words – < 1% |
| 26 | "Abstracts of the EASD, Vienna 2009", Diabetologia,
09/2009
<small>CrossCheck</small> | 8 words – < 1% |
| 27 | www.edctp.org
<small>Internet</small> | 7 words – < 1% |
| 28 | &NA;. "European Society for Paediatric
Gastroenterology, Hepatology, and Nutrition Annual
Meeting June 9–12, 2010 Istanbul, Turkey :", Journal of Pediatric
Gastroenterology & Nutrition, 06/2010
<small>CrossCheck</small> | 7 words – < 1% |
| 29 | www.recentmedicalfindings.com
<small>Internet</small> | 7 words – < 1% |
| 30 | Helen Lydatakis. "Non-invasive markers to predict the
liver fibrosis in non-alcoholic fatty liver disease", Liver
International, 9/2006
<small>CrossCheck</small> | 6 words – < 1% |
| 31 | Henry Marcano. "Limited Weight Loss or Simply No
Weight Gain following Lifestyle-Only Intervention
Tends to Redistribute Body Fat, to Decrease Lipid Concentrations,
and to Improve Parameters of Insulin Sensitivity in Obese
Children", International Journal of Pediatric Endocrinology, 2011
<small>CrossCheck</small> | 6 words – < 1% |

EXCLUDE QUOTES ON
EXCLUDE BIBLIOGRAPHY ON

EXCLUDE MATCHES < 3 WORDS